ViroGates Publishes Prospectus for Public Offering

Mon Jun 04 2018

ViroGates, a diagnostic solutions pioneer, has released its IPO prospectus, heralding a new phase of growth. The strategic move aims to bolster capital for expansion initiatives.

The IPO plan encompasses invigorating commercial efforts, boosting product development, enhancing clinical documentation, and broadening global patent coverage. By issuing new shares and listing on Nasdaq First North, ViroGates targets DKK 60-75 million, with DKK 53.7 million commitments from cornerstone investors.

The capital influx will energize several key strategies:

  • Expanding Commercial Reach (60-70%): A strong sales presence in Europe and strategic partnerships aim to widen the reach of diagnostic solutions.
  • Catalyzing Product Development (10-20%): Funds will propel ongoing innovation in diagnostic solutions.
  • Elevating Clinical Documentation (5-10%): Additional clinical documentation will enhance credibility and user confidence.
  • Global Patent Security (5-10%): Funds will secure global patent coverage for recent suPARnostic® application patent.

ViroGates aspires to achieve positive cash flow by end of 2020 and acquire 40 paying hospital customers, demonstrating a commitment to transformative growth.

In a dynamic medical technology landscape, ViroGates’ IPO propels them toward innovation and impact. The focus now shifts to product innovation and prudent resource use as ViroGates forges ahead, reshaping medical technology through dedication to excellence.

More information to be found in ViroGates´ announcement published on June 4 here;

Read more in the press reviews here (in Danish):

Børsen; Medicoselskab med Coloplast-milliardærer i ryggen vil på børsen; Medicoselskab vil på børsen

MedWatch; ViroGates går på børsen i København

Berlingske; Coloplast-milliardærer bag ny børsnotering


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates